DDInter1125 DDInter1376
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Maraviroc {u} (Compound) binds {v} (Gene) CYP3A4
Maraviroc {u} (Compound) upregulates {v} (Gene) CNPY3
Maraviroc {u} (Compound) is included by {v} (Pharmacologic Class) Chemokine Co-receptor 5 Antagonists
Maraviroc {u} (Compound) downregulates {v} (Gene) NPDC1
Maraviroc {u} (Compound) causes {v} (Side Effect) Herpes virus infection
Maraviroc {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Minoxidil
Maraviroc {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Maraviroc {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Maraviroc {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Maraviroc (Compound) binds CYP3A4 (Gene)
Maraviroc (Compound) upregulates CNPY3 (Gene)
Maraviroc (Compound) is included by Chemokine Co-receptor 5 Antagonists (Pharmacologic Class)
Maraviroc (Compound) downregulates NPDC1 (Gene)
Maraviroc (Compound) causes Herpes virus infection (Side Effect)
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Maraviroc may lead to a major life threatening interaction when taken with Leflunomide
Maraviroc may lead to a major life threatening interaction when taken with Idelalisib